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ABST RACT
Similar to the already well-recognized adenoma-carcinoma sequence in
colorectal cancer pathogenesis, it has been believed for many decades
that the progression of ovarian epithelial tumors occurs from benign
serous cystadenomas to borderline tumors, to well-differentiated
carcinomas, and ultimately, to poorly differentiated carcinomas.
However, it is currently accepted that low-grade serous carcinoma
(LGSC) and high-grade serous carcinoma (HGSC) are fundamentally
different tumor types and, consequently, different diseases. In fact,
whereas the benign-borderline-malignant sequence seems to apply quite
well to low-grade serous carcinoma, the sequence of genetic alterations
in high-grade serous carcinoma is substantially different.
In this mini-review, we included the current consensus regarding the
morphological and etiopathogenic results regarding serous tumors of the
ovary, fallopian tube and peritoneum. It also briefly describes the history
of benign, borderline and malignant serous tumors, discussing multiple
types of dichotomies in serous carcinomas of the female genital tract and
summarizing the current molecular classification.

Introduction
Epithelial tumors of the ovary account for
approximately two-thirds of all ovarian tumors in the
Western world. They encompass a heterogeneous group of
neoplasms that are primary classified based on the cell type
into serous, mucinous, endometrioid, clear cell, transitional
and squamous cell tumors. Based on the fact that the
histologically normal counterparts of these cells are not
usually present in the ovary, their neoplastic presence has
previously been associated with müllerian neometaplasia
of the ovarian surface epithelium (mesothelium), which
evolves from celomic epithelium. Recently, several
scientific studies have provided compelling evidence that
multiple tumors, which were believed to be primary
ovarian cancers, actually originate in other pelvic organs
and involve the ovary as a secondary effect. As a matter of
fact, novel molecular developments demonstrated that
high-grade serous carcinomas might arise from precursor
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lesions in the epithelial lining of the distal fimbria of the
fallopian tube, while endometrioid and clear cell
carcinomas originate from ovarian endometriosis [1-3].
The difference between borderline tumors and
carcinomas is one of the most common problems in ovarian
tumor pathology, yet the literature on borderline tumors is
confusing, particularly with regard to their diagnostic
features and treatment. Although the World Health
Organization recommends the presence of “obvious
invasion” of the stroma as a mandatory criterion for
carcinoma, most pathologists do not require obvious
stromal invasion for the diagnosis if the epithelial cells
feature malignant cytology. In order to address this issue,
the World Health Organization has proposed that such
tumors be classified as borderline serous tumors with
intraepithelial carcinoma. However, the heterogeneity of
ovarian tumors and high inter-observer variability remain
a difficult aspect in gynecological pathology [4-6].
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A thorough search on PubMed using various
combinations of the following headings: “ovarian serous
tumor”, “fallopian serous tumor”, “peritoneal serous
tumor”, “serous borderline tumor”, “low-grade serous
tumor” and “high-grade serous tumor” revealed a total of
94 meta-analyses and systematic reviews published in the
past 10 years. After thoroughly covering these
publications, we have established a mini-review including
the current consensus regarding the morphological and
etiopathogenic results regarding serous tumors of the
ovary, fallopian tubes and peritoneum [5].

Discussions
Benign serous tumors of the ovary and fallopian tube
Benign serous tumors are typically unilateral tumors,
histologically composed of varying amounts of ovariantype stroma and benign tubal-type epithelium. Based on the
predominant histological component, they can be classified
into: serous cystadenoma (predominantly cystic, with
minimal stromal component), serous cystadenofibroma
(predominantly cystic, with abundant stromal component),
serous adenofibroma (predominant stromal component
admixed with small glands) and surface papilloma
(adenofibroma variant with prominent papillae involving
the ovarian surface) [1-3].
Benign serous tumors have a wide age distribution,
usually being diagnosed in the 4th decade. They can be
asymptomatic or present with pelvic pressure and pain,
urinary bladder symptoms or change in bowel habits due to
secondary compression [2]. They can be treated by
cystectomy or oophorectomy and have excellent
prognoses.
The ultrasound examination of the ovarian serous
cystadenoma usually reveals a unilocular cystic or
anechoic adnexal lesion, with no papillary projections. If
any wall irregularity is present, it is thin, with regular
surface and forms an acute angle with the cyst wall. Some
lesions may contain ultrasonographically detectable
septations, but with no flow on color Doppler. Almost all
cystadenofibromas are predominantly cystic with
septations seen in approximately 30% of the cases.
Papillary projections or solid nodules have been
ultrasonographically reported in just over 50% of the cases
[1-4]. Vascularization can be present in less than 50% of
cases, with a typical pattern of peripheral vascularization,
with scattered vessels of high blood flow impedance.
The gross features of benign serous tumors can vary
widely, based on the morphological subtype. Most of them
are unilateral, with a mean size of 8-9 cm. Serous
cystadenomas are more frequently unilocular rather than
multilocular, with clear to straw-colored fluid, minimal
stromal component and smooth inner and outer surfaces.
Some cysts have thick walls and may show internal folds

when the cyst is collapsed. Serous cystadenofibromas
present as variably sized cysts with white-to-gray, firm,
solid areas, containing clear fluid. Firm papillary
excrescences may sometimes be present on the surface.
Serous adenofibromas are predominantly solid, firm, with
white-to-grey homogenous cut surface and scattered small
cysts filled with serous and/or serosanguineous fluid.
Occasionally, serous adenofibromas only involve the
ovarian surface as firm, nodular excrescences (surface
serous papilloma) [5].
Histologically, benign serous tumors are composed of
varying amounts of cysts, glands or papillae lined by a
single layer of serous-type epithelium (cuboidal, columnar
or flattened cells with variable amounts of cilia).
Cystadenofibromas have variably cellular fibromatous
stroma, which may feature areas of edema or hyalinization.
Rarely, psammoma bodies, minor sex cord-like elements,
signet ring stromal elements or ulceration with histiocytes
may be present [6,7].
Immunohistochemically, PAX8, WT1 and ER are
positive in the epithelial component and genetic testing
may reveal copy number changes (trisomy 12) in stromal
cells [8].
The differential diagnosis of benign serous tumors
includes serous borderline tumors, endometriosis,
peritoneal inclusion cysts, hydrosalpinx, cystic struma
ovarii and rete cystadenoma [9].
Serous borderline tumors of the ovary and fallopian
tubes
There are two histological types of serous borderline
tumors: conventional and micro-papillary. Conventional
serous borderline tumors are epithelial neoplasms
composed of papillae with hierarchical branching lined by
fallopian tube-type epithelium showing stratification,
detached cell clusters, and low-grade nuclear atypia
without evidence of frank stromal invasion [10]. Micropapillary serous borderline tumors are epithelial neoplasms
in which papillae show abrupt transition from central
fibrovascular cores to long, slender papillae which are
usually five-times longer than wider, lined by cuboidal
tubal-type epithelium without evidence of frank stromal
invasion [11-13].
Serous borderline tumors represent 4% of all ovarian
tumors and 10-15% of all ovarian serous tumors. The mean
age at presentation is 42-50 years [14]. Most patients are
asymptomatic, while others may present with abdominal
pain, distention or ascites [15].
Serous borderline tumors are usually larger than 5 cm
and frequently bilateral, especially the micro-papillary
variant. They show velvety projections and/or nodularity,
which are white-to-yellow, soft, friable and most of the
times intracystic, with or without surface involvement. The
45
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cystic space is filled with viscous or serous fluid and
hemorrhage or necrosis are typically absent [16].
The histological architecture of conventional serous
borderline tumors shows hierarchical branching of papillae
with irregular contours, ending with detached cell clusters
and single cells (budding/tufting). The wall of the cyst is
composed of variable amounts of fibromatous stroma,
which may show ulceration, hemosiderin deposition and
foamy histiocytes [17]. Cytologically, the fibrovascular
cores are lined by non-stratified or pseudostratified
columnar or cuboidal cells, with low-grade nuclear atypia
and small nucleoli. The cells may be ciliated or show clear
or focal apical mucinous cytoplasm. Pregnant patients may
also have variable numbers of polygonal and hobnail cells
with eosinophilic cytoplasm. The histological architecture
of micro-papillary serous borderline tumors is
characterized by a central edematous papilla with abrupt
transition to delicate, filiform micro-papillae without
fibrovascular cores, which are five-times longer than
wider. This structure is often referred to as “caput
medusae”. Sometimes, the fusion of the micro-papillae can
lead to a cribriform appearance [18]. Cytologically, the
cells are cuboidal, with small, uniform nuclei, often with
prominent nucleoli, high nuclear to cytoplasmic ratio and
typical lack of cilia.
Conventional and micro-papillary patterns may be
admixed. In order to fall into the micro-papillary category,
micro-papillary patterns must measure more than 5 mm in
continuous extent or represent at least 10% of the tumor. If
these criteria are not met, the tumor should be classified as
serous borderline tumor with focal micro-papillary features
[19].
Serous borderline tumors may show foci of
microinvasion, noninvasive epithelial or desmoplastic
implants, invasive implants and even lymph node
involvement.
Microinvasion is present in 10% of all serous
borderline tumors and may show multiple histological
patterns, which can coexist within the same tumor.
Microinvasion is characterized by single cells, clusters of
cells or small papillae floating in cleft-like spaces.
Sometimes, this so-called “inside-out pattern” may
represent lymphatics. In this case, immunohistochemistry
for D2-40 can be useful. The area of microinvasion must
measure less than 10 mm2 or less than 5 mm in its greatest
extent. If the area is larger, the tumor should be classified
as low-grade serous carcinoma [20].
Peritoneal implants are present in 30% of all serous
borderline tumors [13,21]. They are more frequent in
patients who have an exophytic component than in those
that do not. Non-invasive implants are confined to the
surface of organs. Non-invasive epithelial implants appear
on peritoneal surfaces, as papillary proliferations or
detached clusters of cells resembling those in ovarian SBT,
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confined within well demarcated cystic spaces or
invaginations, lined by a single layer of serous cells. They
are frequently associated with psammomatous
calcifications. Non-invasive desmoplastic implants appear
on peritoneal surfaces or ovarian surface (autoimplants) as
single cells, clusters of cells, small papillae, or irregularly
shaped glands with mild cytologic atypia, entrapped in a
desmoplastic or granulation tissue-like stroma, which is the
predominant component. They are also well demarcated
from the underlying tissues. Invasive implants appear as
small papillae, micro-papillae, small and large irregular
glands, solid nests or single cells with destructive invasion
of underlying tissues and desmoplastic response [22].
Lymph node involvement in patients with ovarian
serous borderline tumors varies between 20% to 30%.
However, most clinical studies with follow-up data
indicate that the lymph node status is not an independent
prognostic factor for the patient’s survival [23].
Serous
borderline
tumors
show
positive
immunoreaction for CK7, PAX8, CA125, WT1, ER and
PR [24]. Calretinin and p16 can be patchy positive or
negative and p53 shows a wild-type pattern of expression
(scattered positive cells) [25,26]. Genetic testing reveals
BRAF and KRAS mutations with 95% concordance in
serous borderline tumors and associated implants [27,28].
The differential diagnosis includes serous cystadenoma
with focal epithelial proliferation, low-grade serous
carcinoma, high-grade serous carcinoma, seromucinous
borderline tumor, endometrioid borderline tumor, clear cell
carcinoma, retiform variant of Sertoli-Leydig cell tumor,
peritoneal
low-grade
serous
carcinoma
and
endosalpingiosis [28-31].
The serous borderline tumor of the peritoneum
The serous borderline tumor of the peritoneum is a lowgrade epithelial neoplasm of tubal-type cells with cellular
proliferation and stratification, without underlying tissue
invasion. For a serous borderline tumor to be designated as
primary peritoneal, the ovaries must be grossly and
microscopically normal or enlarged only by benign
processes [32].
Serous borderline tumors of the peritoneum are rare,
with a peak incidence between the 4th and the 5th decades
of life, have no association with BRCA1 or BRCA2
mutations and most commonly affect the pelvis or both the
pelvis and the abdominal cavity.
Clinically, patients may present with pelvic pain,
pressure, discomfort, ascites, vaginal bleeding or
infertility, but most serous borderline tumors are usually
asymptomatic and detected incidentally. Occasionally,
they can be identified upon imaging investigations due to
the presence of psammoma bodies in the Papanicolau
smear [33,34].
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The treatment involves hysterectomy with bilateral
salpingo-oophorectomy
with
removal
of
any
pelvic/omental tumor. If fertility is desired, the
conservative approach may be considered. At the time of
writing, chemotherapy or radiation have no established role
in the therapeutic management of serous borderline tumors
of the peritoneum. Most tumors have a favorable
prognosis, but recurrences are common. If these tumors
progress to serous carcinomas, adverse outcomes are very
likely and most patients die from the disease.
Grossly, serous borderline tumors of the peritoneum
appear as adhesions simulating the inflammatory pelvic
disease with individual nodules smaller than 1 cm.
From a histopathological point of view, serous
borderline tumors resemble non-invasive or desmoplastic
implants of ovarian serous borderline tumors and are
composed of papillae, nests, glands, clusters of cells or
single cells with tufting, budding and epithelial pseudostratification. The cells are uniform, cuboidal or columnar,
with eosinophilic cytoplasm and round nuclei, with small
nucleoli [35].
The differential diagnosis includes primary peritoneal
low-grade serous carcinoma, non-invasive implants of
ovarian serous borderline tumor, well-differentiated
papillary mesothelioma or malignant mesothelioma and
endosalpingiosis with focal atypia [36-38].
Low-grade serous carcinomas of the ovary and
fallopian tubes
The low-grade serous carcinoma is a malignant
epithelial neoplasm of serous cell lineage with distinctive
architecture, low-grade nuclear atypia and destructive
invasion.
Low-grade serous carcinoma is less frequent than highgrade serous carcinoma, accounting for 3.5% of all ovarian
carcinomas and 5% of all serous carcinomas [39]. It usually
affects patients in the 6th decade of life and it can be
diagnosed incidentally or present with abdominal swelling
or pain. Low-grade serous carcinomas are usually high
stage at presentation and may be a recurrence of a previous
serous borderline tumor. Most tumors tend to have an
indolent course with progressive disease. The therapeutic
management involves bilateral salpingo-oophorectomy
and hysterectomy with debulking and staging biopsies.
Imaging techniques play an important role in the
diagnosis of ovarian carcinoma and in the assessment of
the metastatic disease. However, surgical and
histopathological examinations remain the standard of care
for staging the disease [40]. Typical imaging features of
ovarian serous carcinomas include: the presence of a cystic
adnexal mass with substantial solid components,
associated with ascites, peritoneal nodularity and
lymphadenopathy. Calcification can be seen in
approximately 12% of the cases, but it also appears in
serous cystadenoma and other tumors [41].

Low-grade serous carcinomas are typically bilateral,
solid or both solid and cystic with multiple polypoid
excrescences and little, if any, necrosis. Solid areas may
have gritty surfaces due to calcifications. Most tumors
show a non-invasive serous borderline component, with or
without a micro-papillary pattern [42].
The histological examination of low-grade serous
carcinomas will reveal both non-invasive and invasive
patterns [43]. Non-invasive patterns are represented by tall
and slender to rounded bud-like papillae with variable
cellularity as well as solid, fenestrated or cribriform areas
of epithelial proliferation. Cytologically, the cells show
low-grade nuclear atypia with prominent nucleoli. Invasive
patterns must measure more than 5 mm in continuous
extent and may be represented by micro-papillae, small
papillae, small or large nests or inverted micro-papillae in
cleft-like spaces. Rarely, single cells, signet cells, solid,
cribriform or glandular patterns of growth may show
haphazard invasion and desmoplastic stromal reaction.
Psammoma bodies are common and variably numerous.
Necrosis and cytological pleomorphism are rare [44].
The immunohistochemical profile of low-grade serous
carcinoma is very similar to that of its high-grade
counterpart [45]. The only significant differences are wildtype pattern of expression for p53 and lower Ki67 index in
low-grade serous ovarian carcinomas. B-RAF and K-RAS
mutations are present in 38% and 19% of cases,
respectively [46]. Low-grade serous carcinomas do not
show chromosomal instability and lack the complex
genetic abnormalities seen in high-grade serous
carcinomas. Moreover, low-grade serous carcinomas are
not associated with BRCA germline mutations [47,48].
The differential diagnosis of low-grade serous ovarian
carcinoma includes high-grade serous carcinoma, serous
borderline tumor, endometrioid borderline tumor and
malignant mesothelioma secondarily involving the ovary.
High-grade serous carcinomas of the ovary and
fallopian tubes
The high-grade serous carcinoma is a malignant
epithelial
tumor
showing
serous
(tubal-type)
differentiation with papillary, solid and/or glandular
growth and moderate to severe nuclear atypia [49].
The high-grade serous ovarian carcinoma is the most
common type of ovarian cancer, accounting for
approximately 70% of all ovarian carcinomas. It usually
affects slightly older women than the low-grade serous
ovarian carcinoma (the 6th to the 7th decade of life) [50].
Although most patients have symptoms, these are often
subtle or nonspecific and easily confused with those of
benign conditions of the gastrointestinal and urinary tracts.
Because of this, up to 80% of the patients present with
advanced stage disease and tumors confined to the ovary at
diagnosis are extremely uncommon. The clinical features
include pelvic pain, gastrointestinal symptoms, increased
47
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abdominal girth due to ascites, urinary frequency, dysuria
and vaginal bleeding [51].
High grade serous ovarian carcinomas range in size
from microscopic to over 20 cm in diameter and are
bilateral in 60% of all cases. The papillae tend to be softer
and more confluent than those in serous borderline tumors.
Poorly differentiated tumors are predominantly solid,
multinodular masses with extensive areas of necrosis and
hemorrhage [52].
Histologically, high-grade serous ovarian tumors show
multiple architectural patterns, frequently admixed,
including: hierarchical branching of variably sized papillae
with cellular tufting and budding, bridging and fusion of
papillae with formation of slit-like spaces, solid, pseudoendometrioid,
transitional
cell
carcinoma-like,
microcystic, glandular or micro-papillary patterns [53,54].
Cytologically, the proliferation is composed of columnar
to cuboidal epithelial cells with variable amounts of
eosinophilic and sometimes clear cytoplasm, showing
high-grade nuclear atypia, often with severe pleomorphism
and more than 3-fold variation in nuclear size. Necrosis is
frequent and extensive. The mitotic index is high
(typically >12 mitoses / 10HPF), with mostly atypical
forms. Solid, pseudo-endometrioid and transitional cell
carcinoma-like morphology, as well as tumor infiltrating
lymphocytes are more common in patients with BRCA1
mutation, but these features are not pathognomonic of that
setting. Psammoma bodies can be present, but are less
numerous than in low-grade serous ovarian carcinomas. If
sampled accordingly, most high-grade serous ovarian
carcinomas will reveal the association with serous tubal
intraepithelial carcinoma. Although low-grade and highgrade serous ovarian carcinoma typically develops
independently, in some cases, a morphologic continuum
may be seen.
The assignment of primary site for high-grade serous
carcinoma (ovary vs. fallopian tube vs. peritoneum) is
arbitrary and has no clinical relevance. Singh et al.
proposed the following scheme for assigning the site of
origin: primary ovarian for dominant ovarian masses
without serous tubal intraepithelial carcinoma and primary
tubal for dominant ovarian masses with serous tubal
intraepithelial carcinoma [51,52].
Most high-grade serous carcinomas show either diffuse
positivity or complete absence of p53 and strong and
diffuse staining for p16 in approximately 60% of the cases.
Ki67 is usually > 75% and Napsin-A and HNF-1β are
negative [53, 54].
The differential diagnosis includes low-grade serous
carcinoma, clear cell carcinoma, undifferentiated
carcinoma, endometrioid carcinoma, metastatic serous
carcinoma, metastatic breast carcinoma and malignant
mesothelioma [55-58].
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Serous carcinomas of the peritoneum
The serous carcinoma of the peritoneum is a malignant
neoplasm showing tubal-type differentiation. For a serous
carcinoma to be designated as primary peritoneal, the
ovaries and fallopian tubes must be grossly and
microscopically normal or altered only by benign
processes and no evidence of primary ovarian, tubal or
uterine serous carcinoma (including serous intraepithelial
carcinoma) should be found [59].
Both low-grade and high-grade serous carcinomas of
the peritoneum are extremely rare, with a continuously
decreasing incidence due to the increased recognition of
fallopian tube primary tumors. Low-grade serous
carcinomas usually affect patients in the 5th decade of life,
while high-grade serous carcinomas appear 2 decades later.
Symptoms, if present, can include malaise, increasing
girth, changes in bowel habits and abdominal pain [60].
Low-grade serous carcinomas of the peritoneum have a
relatively indolent course, but they are usually
chemoresistant. On the other hand, high-grade serous
carcinomas are initially chemosensitive, but recur
frequently. The therapeutic management involves
hysterectomy with bilateral salpingo-oophorectomy,
omentectomy and the surgical removal of any
macroscopically visible tumor, followed by platinum
chemotherapy [61].

Conclusions
Ovarian cancer remains the most lethal neoplasm in
gynecological oncological pathology and malignant
epithelial tumors are the most common subtype,
accounting for 90% of the cases. Although traditionally
referred to as a single entity, ovarian cancer is not a
homogenous disease but rather a group of diseases with
variable morphology and biologic behavior. Based on the
histopathological, immunohistochemical and molecular
genetic analyses, there are at least five subtypes of ovarian
carcinomas: high-grade serous carcinomas, endometrioid
carcinomas, clear cell carcinomas, mucinous carcinomas
and low-grade serous carcinomas. These tumors account
for 98% of the ovarian carcinomas, can be reproducibly
diagnosed by light microscopy and are inherently different
diseases, as indicated by differences in epidemiologic and
genetic risk factors, precursor lesions, patterns of spread,
molecular events during oncogenesis, response to
chemotherapy and prognosis.
In this review, we briefly described the history of
benign, borderline and malignant serous tumors, discussed
multiple types of dichotomies in serous carcinomas of the
female genital tract and summarized the current molecular
classification. Although traditionally, ovarian tumors were
diagnosed based on morphology alone, the current
concepts have shifted to a combination of histologic and
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molecular findings. While the importance of
histopathological examination in unravelling the origins of
high-grade serous carcinoma is undeniable, future
molecular findings could rank at the top of an integrated
diagnosis system for making a decision.
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